Skip to main content

Table 1 Clinical characteristics of acute lymphoblastic leukemia survivors

From: Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors

 

Childhood ALL survivors

Females

Males

Total

239

120

119

Age at visit (y)

21.5 ± 6.1

21.5 ± 6.3

21.6 ± 6.0

Age at cancer diagnosis (y)

6.3 ± 4.6

6.2 ± 4.4

6.4 ± 4.7

Time from the end of the treatment (y)

13.0 ± 5.0

13.0 ± 5.3

12.9 ± 4.8

Weight (kg)

66.8 ± 16.4

63.7 ± 16.6

70.0 ± 15.7

Height (cm)

166.9 ± 10.0

160.3 ± 6.7

171.5 ± 9.6

\( \dot{\mathrm{V}} \)O2 peak (mL.kg− 1.min− 1)

32.6 ± 8.4

27.6 ± 6.5

36.9 ± 7.4*

Power at \( \dot{\mathrm{V}} \) O2 peak (W)

174.7 ± 55.3

133.5 ± 28.9

213.8 ± 45.0*

\( \dot{\mathrm{V}} \)O2 peak predicted (%)

85.7 ± 17.1

86.8 ± 18.3*

83.2 ± 15.4

Physical activity (min)

27.8 ± 29.4

24.9 ± 30.3

30.5 ± 28.4*

DOX (mg/m2)

182.8 ± 119.7

183.4 ± 121.9

182.2 ± 117.9

DEX (mg/m2)

2781.0 ± 440.0

2828.8 ± 374.4

2731.8 ± 499.4

  1. ALL acute lymphoblastic leukemia, DOX cumulative dose of doxorubicin, DEX cumulative dose of dexrazoxane. Physical activity variable represents minutes per day of moderate or intense leisure physical activities. Data are expressed as percentage or as means ± SD. *p < 0.05, Females versus Males